n-undecanoic acid sodium salt | 17265-30-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: n-undecanoic acid sodium salt
• 英文别名: sodium hendecanoate；sodium undecanoate；sodium;undecanoate
• CAS: 17265-30-4
• 化学式: C₁₁H₂₁O₂*Na
• 分子量: 208.276
• InChiKey: ZOOPHYLANWVUDY-UHFFFAOYSA-M

物化性质

• LogP：
  4.497 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.73
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  {Pd(C10H21OC6H3CH=NN=CHC6H4OC10H21)(μ-Cl)}2 、 n-undecanoic acid sodium salt 以 丙酮 为溶剂， 以80%的产率得到{Pd(H21C10OC6H3CH=NN=CHC6H4OC10H21)(μ-O2CC10H21)}2
  参考文献：
  名称：

  非平面介晶的合成，表征和X射线研究：羧基桥联的正钯嗪复合物

  摘要：

  DOI：

  10.1021/om00157a010
• 作为产物：
  描述：

  十一烷酸 在 碳酸氢钠 作用下， 以 乙醇 、 水 为溶剂， 生成 n-undecanoic acid sodium salt
  参考文献：
  名称：

  A Simple and Efficient Large-Scale Synthesis of Metal Salts of Medium-Chain Fatty Acids

  摘要：

  A simple, inexpensive, one-step general procedure was developed for the preparation of medium-chain fatty acid (MCFA) metal salts. This approach offers the advantage of a practical route and is superior to literature methods. Also, it overcomes many of the limitations previously reported for the preparation of fatty acid salts. The potential utility of this method is illustrated by the production of pilot-scale quantities of high-purity (>99.9%) sodium decanoate.

  DOI：

  10.1021/op900038v

文献信息

• [EN] NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVELLES DIHYDROPYRIDOISOQUINOLINONES ET LEURS COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2016169911A1

  公开（公告）日：2016-10-27

  A compound according to Formula (I): wherein R1, LA, CyA, RA, R2, R3, and R4 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions, pain, neuroinflammatory conditions, neurodegenerative conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, cardiovascular diseases, leukemia, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  根据公式（I）的化合物：其中R1、LA、CyA、RA、R2、R3和R4如本文所述。本发明涉及根据公式I的新化合物，这些化合物拮抗GPR84，GPR84是涉及炎症状况的G蛋白偶联受体，以及制备这些新化合物的方法，包括这些化合物的药物组合物，以及通过给予本发明的化合物预防和/或治疗炎症状况、疼痛、神经炎症状况、神经退行性疾病、传染病、自身免疫疾病、内分泌和/或代谢疾病、心血管疾病、白血病和/或通过给予本发明的化合物导致免疫细胞功能受损的疾病的方法。
• Preparation of an Olefin Oligomerization Catalyst
  申请人：Sydora Orson L.

  公开号：US20130150642A1

  公开（公告）日：2013-06-13

  This disclosure provides for new catalyst systems and new methods for preparing and using the catalyst systems for generating a trimerization product. In an aspect, the new catalyst systems comprise a chromium carboxylate that is prepared by anhydrous metathesis. In another aspect, the catalyst system comprise a chromium carboxylate that is prepared by anhydrous metathesis and a metal pyrrolide compound. The catalyst systems imparts improved performance and/or reduced catalyst system cost to an olefin trimerization process.

  本公开提供了新的催化剂系统和新的方法，用于制备和使用催化剂系统生成三聚物产物。在一个方面，新的催化剂系统包括通过无水交换反应制备的铬羧酸盐。在另一个方面，催化剂系统包括通过无水交换反应制备的铬羧酸盐和金属吡咯烷化合物。这些催化剂系统赋予烯烃三聚化过程改进的性能和/或降低了催化剂系统成本。
• Preparation of Transition Metal Carboxylates
  申请人：Sydora Orson L.

  公开号：US20130150605A1

  公开（公告）日：2013-06-13

  This disclosure provides a process for making transition metal carboxylate compositions by combining in an polar aprotic first solvent a transition metal precursor and a Group 1 or Group 2 metal carboxylate under substantially acid-free and substantially anhydrous conditions, to generate a mixture comprising the transition metal carboxylate composition. Optionally, the transition metal carboxylate composition can be purified, for example, by substantially removing the first solvent provide a residue comprising the transition metal carboxylate composition, and also optionally, further by extracting the transition metal carboxylate composition from the residue with a non-coordinating second solvent to provide an extract comprising the transition metal carboxylate composition.

  本公开提供了一种制备过渡金属羧酸盐组合物的方法，包括在极性无质子的第一溶剂中，在基本无酸和基本无水的条件下，将过渡金属前体和1组或2组金属羧酸盐组合，生成包含过渡金属羧酸盐组合物的混合物。可选地，可以通过基本去除第一溶剂来提纯过渡金属羧酸盐组合物，得到包含过渡金属羧酸盐组合物的残留物，还可以选择性地通过使用非配位的第二溶剂从残留物中提取过渡金属羧酸盐组合物，得到包含过渡金属羧酸盐组合物的提取物。
• Solid oral dosage form containing an enhancer
  申请人：——

  公开号：US20030091623A1

  公开（公告）日：2003-05-15

  The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

  本发明涉及一种固体口服剂型，其中包含一种具有药理活性成分的增强剂，该增强剂增强了活性成分的生物利用度和/或吸收。因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯、醚或盐或中链脂肪酸的衍生物，最好是在室温下为固体，碳链长度为6至20个碳原子。最好，固体口服剂型是控释剂型，例如延迟释放剂型。
• COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER
  申请人：Ben-Sasson A. Shmuel

  公开号：US20070219131A1

  公开（公告）日：2007-09-20

  This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.

  本发明涉及一种新型渗透组合物，其中包括一个或多个效应物质，这些效应物质被包含在可溶于水的组合物中，并浸入到疏水介质中。本发明还涉及通过将这种渗透组合物用于受影响的主体来治疗或预防疾病的方法。